Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

Summary of Consolidated Financial Results for the First Quarter of FY2026 (from April 1, 2026 to June 30, 2026) (Under Japanese GAAP)

August 4, 2026

Listed Company Name: ASKA Pharmaceutical Holdings Co., Ltd. Stock exchange listings: Tokyo Prime

Securities Code: 4886 URL: https://www.aska-pharma-hd.co.jp/english/

Representative: (Job title) President, Member of the Board of Directors, Representative Director (Name) Sohta Yamaguchi

Inquiries: (Job title) Director, Corporate Planning Department (Name) Manabu Ichikawa Telephone: +81-3-5484-8366

Scheduled Dividend Payment Start Date: —

Availability of Supplementary Financial Materials: Yes

Availability of Financial Results Briefing: No

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated Financial Results for the First Quarter of the Fiscal Year Ending March 2027 (April 1 2026 – June 30, 2026)

(1) Consolidated Operating Results (Cumulative) (Percentages indicate year-on-year changes.)

	Net Sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
Three months ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
June 30, 2026	17,384	(1.5)	711	(51.4)	817	(48.7)	533	(57.5)
June 30, 2025	17,641	7.9	1,464	(16.7)	1,594	(12.1)	1,255	(1.4)

(Note) Comprehensive Income First Quarter of Fiscal Year Ending March 2027 ¥1,413 million 90.7% First Quarter of Fiscal Year Ended March 2026 ¥741 million (62.3)%

	Basic earnings per share	Diluted Earnings per Share
Three months ended	Yen	Yen
June 30, 2026	18.78	—
June 30, 2025	44.27	—

(Note) In the previous consolidated fiscal year, the finalization of provisional accounting treatment for business combinations was carried out, and the various figures for the first quarter of the fiscal year ended March 2026 reflect the content of the finalized provisional accounting treatment.

(2) Consolidated Financial Position

	Total assets	Net assets	Equity Ratio
As of	Millions of yen	Millions of yen	%
June 30, 2026	109,905	77,296	64.4
March 31, 2026	112,379	76,819	62.6

Reference: Equity First Quarter of Fiscal Year Ending March 2027 ¥70,768 million Fiscal Year Ended March 31, 2026 ¥70,360 million

2. Cash dividends

	Annual Dividends per Share				
	End of First Quarter	End of Second Quarter	End of Third Quarter	Fiscal Year-End	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal Year Ended March 31, 2026	—	27.00	—	33.00	60.00
Fiscal Year Ending March 31, 2027	—				
Fiscal Year Ending March 31, 2027 (Forecast)		32.00	—	33.00	65.00

(Note) Revisions to the most recently announced dividend forecast: None

3. Consolidated Earnings Forecast for the Fiscal Year Ending March 31, 2027 (April 1, 2026 – March 31, 2027)

(Percentages indicate year-on-year changes.)

	Net Sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Full Year	73,000	2.6	6,200	6.3	6,100	7.7	4,800	(11.5)	169.11

(Note) Revisions to the most recently announced financial forecast: None

* Notes

(1) Significant changes in the scope of consolidation during the period: No

Newly included: — (Company name: —)

Excluded: — (Company name: —)

(2) Application of accounting procedures specific to the preparation of quarterly consolidated financial statements: No

(3) Changes in accounting policies, changes in accounting estimates, and restatements

(i) Changes in accounting policies due to revisions to accounting standards and other regulations: None

(ii) Changes in accounting policies other than those described in (i): None

(iii) Changes in accounting estimates: None

(iv) Restatements: None

(4) Number of issued shares (common stock)

(i) Total number of shares issued and outstanding at period-end (including treasury stock)	As of June 30, 2026	28,763,199 shares	As of March 31, 2026	28,763,199 shares
(ii) Number of treasury shares at period-end	As of June 30, 2026	367,085 shares	As of March 31, 2026	367,085 shares
(iii) Average number of shares outstanding during the period (cumulative)	Three months ended June 30, 2026	28,396,114 shares	Three months ended June 30, 2025	28,363,633 shares

* Review of the attached consolidated quarterly financial statements by certified public accountants or auditing firm: No

* Explanation Concerning the Appropriate Use of Financial Forecasts and Other Special Notes

The earnings forecasts and other forward-looking statements contained in this document are based on information currently available to the Company and on certain assumptions deemed reasonable by the Company, and are not intended as a guarantee of future performance. Furthermore, actual results may differ significantly due to various factors. For information regarding the assumptions underlying the financial forecasts and precautions, etc., regarding the use of such forecasts, please refer to "1. Overview of Operating Results, etc. (3) Explanation of Forward-Looking Information such as Consolidated Financial Forecasts" in the attached materials.

• Table of Contents of Attached Materials

1. Overview of Operating Results

(1) Overview of Operating Results for the Current Quarter

During the first quarter of the current consolidated fiscal year, the domestic economy showed a gradual recovery trend, supported by improvements in employment and income conditions. However, the situation remains uncertain due to continued price increases, developments in U.S. trade policy, and geopolitical risks such as the situation in the Middle East. The Group's core pharmaceutical business continues to face a challenging business environment due to ongoing drug price revisions, rising manufacturing costs, and other factors. Under these business conditions, net sales decreased by ¥257 million YoY to ¥17,384 million (down 1.5% YoY). In terms of profitability, due to increases in cost of sales, research and development expenses, and other factors, operating profit was ¥711 million (down 51.4% YoY), ordinary profit was ¥817 million (down 48.7% YoY), and quarterly profit attributable to owners of parent was ¥533 million (down 57.5% YoY).

The Company's consolidated operating results for the first quarter of the current fiscal year are as follows:

	First Quarter of the Previous Fiscal Year, Consolidated Cumulative Period (Millions of yen)	First Quarter of the Current Fiscal Year, Consolidated Cumulative Period (Millions of yen)	Change (Millions of yen)	Change (%)
Net Sales	17,641	17,384	(257)	(1.5)
Operating profit	1,464	711	(753)	(51.4)
Ordinary profit	1,594	817	(776)	(48.7)
Profit attributable to owners of parent	1,255	533	(722)	(57.5)

Segment results are as follows:

(i) Pharmaceutical Business

The pharmaceutical business, which focuses on the three fields of internal medicine, obstetrics and gynecology, and urology, remained in line with the previous fiscal year despite the impact of annual NHI drug price revisions. By product, sales of "RELUMINA," a treatment for uterine fibroids and endometriosis in the obstetrics and gynecology field, remained at the same level as the previous fiscal year, at ¥2,776 million (up 0.3% YoY). In comparison, sales of "DroEthi," a treatment for dysmenorrhea, came to ¥1,946 million (down 3.8% YoY). Sales of "THYRADIN," a thyroid hormone agent and mainstay product in the internal medicine field, grew steadily to ¥2,257 million (up 6.2% YoY), partly aided by a positive revision in drug prices, while "RIFXIMA," a poorly absorbed rifamycin-based antimicrobial agent, also performed well, reaching ¥1,982 million (up 4.2% YoY). In the urology field, sales of 'LEUPRORELIN,' an LH-RH derivative microcapsule sustained-release agent, amounted to ¥1,064 million (up 10.5% YoY).
As a result of the above, net sales were ¥14,484 million (down 0.2% YoY), remaining at the same level as the previous fiscal year. However, segment profit was ¥1,132 million (down 33.3% YoY) due to increases in cost of sales driven by rising raw material prices and other costs, as well as research and development expenses associated with the progress of clinical trials, among other factors.

(ii) Animal Health Business

In the animal health business, which sells veterinary pharmaceuticals, feed additives, and other products, net sales were ¥1,952 million (up 6.1% YoY), driven mainly by livestock pharmaceuticals and feed additives. However, segment profit was ¥44 million (down 65.4% YoY) due to an increase in procurement prices for feed additives caused by the weaker yen and geopolitical risks.

(iii) Overseas Business

At Ha Tay Pharmaceutical Joint Stock Company, a Vietnamese pharmaceutical company, net sales were ¥908 million (down 25.9% YoY) and a segment loss of ¥35 million was recorded (compared to a segment profit of ¥58 million in the same period of the previous fiscal year). This downturn was due to difficulties in procuring active pharmaceutical ingredients from the Middle East for its mainstay products.

(iv) Other Businesses

In the Other Businesses segment, which operates in areas such as clinical testing services and medical devices, net sales were ¥38 million (down 33.4% YoY), and a segment loss of ¥8 million was recorded (compared to a loss of ¥2 million in the same period of the previous fiscal year).

*For net sales of mainstay products, please refer to “3. Supplementary Information”.

(2) Overview of Financial Position for the Current Quarter

(Assets)

Total assets at the end of the first quarter of the current consolidated fiscal year decreased by ¥2,474 million from the end of the previous consolidated fiscal year to ¥109,905 million. This was primarily due to a decrease in cash and deposits, other current assets, and other factors.

(Liabilities)

Total liabilities at the end of the first quarter of the current consolidated fiscal year decreased by ¥2,951 million from the end of the previous consolidated fiscal year to ¥32,608 million. This was primarily due to a decrease in other current liabilities, other provisions, and other factors.

(Net Assets)

Total net assets at the end of the first quarter of the current consolidated fiscal year increased by ¥477 million from the end of the previous consolidated fiscal year to ¥77,296 million. This was primarily due to an increase in the valuation difference on available-for-sale securities.

The equity ratio increased by 1.8 percentage points from the end of the previous consolidated fiscal year to 64.4%.

(3) Explanation of Forward-Looking Information, Including Consolidated Earnings Forecast

There are no changes to the consolidated earnings forecasts for the fiscal year ending March 2027, from the full-year consolidated earnings forecasts announced in the "Consolidated Financial Results for the Fiscal Year Ended March 31, 2026" on May 11, 2026.

(4) Explanation of R&D Activities

Total research and development expenses for the first quarter of the current consolidated fiscal year amounted to ¥2,582 million.

2. Quarterly Consolidated Financial Statements and Notes

(1) Quarterly Consolidated Balance Sheets

(Millions of yen)

	As of March 31, 2026	As of June 30, 2026
Assets		
Current assets		
Cash and deposits	10,126	7,108
Accounts receivable - trade	16,022	16,588
Merchandise and finished goods	14,743	15,068
Work in process	416	727
Raw materials and supplies	14,022	13,366
Other	6,159	4,544
Allowance for doubtful accounts	(67)	(50)
Total current assets	61,424	57,353
Non-current assets		
Property, plant and equipment	19,244	19,022
Intangible assets		
Goodwill	2,354	2,339
Other	6,514	6,278
Total intangible assets	8,869	8,618
Investments and other assets		
Investment securities	17,299	20,136
Deferred tax assets	2,085	1,515
Other	3,474	3,276
Allowance for doubtful accounts	(17)	(17)
Total investments and other assets	22,841	24,910
Total non-current assets	50,955	52,551
Total assets	112,379	109,905
Liabilities		
Current liabilities		
Accounts payable - trade	5,288	4,751
Electronically recorded obligations - operating	2,270	2,222
Short-term borrowings	3,269	4,163
Other provisions	1,317	503
Other	10,145	8,200
Total current liabilities	22,291	19,841
Non-current liabilities		
Long-term borrowings	8,165	7,672
Retirement benefit liability	23	23
Other	5,080	5,071
Total non-current liabilities	13,268	12,767
Total liabilities	35,559	32,608
Net assets		
Shareholders' equity		
Share capital	1,197	1,197
Capital surplus	31	—
Retained earnings	63,352	62,978
Treasury shares	(658)	(658)
Total shareholders' equity	63,923	63,517
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	5,646	6,449
Foreign currency translation adjustment	(292)	(249)
Remeasurements of defined benefit plans	1,083	1,050
Total accumulated other comprehensive income	6,437	7,250
Non-controlling interests	6,459	6,528
Total net assets	76,819	77,296
Total liabilities and net assets	112,379	109,905

(2) Quarterly Consolidated Statements of Income and Comprehensive Income
(Quarterly Consolidated Statement of Income)

(Millions of yen)

	Three months ended June 30, 2025	Three months ended June 30, 2026
Net sales	17,641	17,384
Cost of sales	9,012	9,295
Gross profit	8,629	8,088
Selling, general and administrative expenses	7,164	7,377
Operating profit	1,464	711
Non-operating income		
Interest income	63	14
Dividend income	164	180
Other	47	100
Total non-operating income	274	295
Non-operating expenses		
Interest expenses	51	93
Share of loss of entities accounted for using equity method	4	63
Other	89	32
Total non-operating expenses	145	189
Ordinary profit	1,594	817
Extraordinary income		
Gain on sale of non-current assets	96	―
Total extraordinary income	96	―
Profit before income taxes	1,690	817
Income taxes - current	570	83
Income taxes - deferred	(209)	201
Total income taxes	361	285
Profit	1,329	532
Profit (loss) attributable to non-controlling interests	73	(0)
Profit attributable to owners of parent	1,255	533

(Quarterly Consolidated Statement of Comprehensive Income)

(Millions of yen)

	Three months ended June 30, 2025	Three months ended June 30, 2026
Profit	1,329	532
Other comprehensive income		
Valuation difference on available-for-sale securities	97	804
Foreign currency translation adjustment	(670)	140
Remeasurements of defined benefit plans, net of tax	(16)	(32)
Share of other comprehensive income of entities accounted for using equity method	1	(30)
Total other comprehensive income	(588)	880
Comprehensive income	741	1,413
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	990	1,346
Comprehensive income attributable to non-controlling interests	(249)	67

(3) Notes to the Quarterly Consolidated Financial Statements

(Notes on the Going Concern Assumption)

Not applicable.

(Notes on Significant Changes in Shareholders' Equity)

Not applicable.

(Notes on the Quarterly Consolidated Cash Flow Statement)

A quarterly consolidated cash flow statement for the first quarter of the current consolidated fiscal year (cumulative) has not been prepared. In addition, depreciation and amortization expenses for the first quarter of the current consolidated fiscal year (cumulative period) (including amortization of intangible assets, excluding goodwill) are as follows:

	First Quarter of the Previous Consolidated Fiscal Year (Cumulative) (April 1, 2025 – June 30, 2025)	First Quarter of the Current Consolidated Fiscal Year (Cumulative) (April 1, 2026 – June 30, 2026)
Depreciation	¥617 million	¥697 million

Note As described in "(Notes on Business Combinations)," during the previous fiscal year, the provisional accounting treatment for the business combination was finalized. Accordingly, depreciation for the first quarter of the previous fiscal year reflects the significant revision to the initial allocation of the acquisition cost resulting from the finalization of the provisional accounting treatment.

(Notes on Segment Information, etc.)

[Segment Information]

I. First Quarter of the Previous Consolidated Fiscal Year (Cumulative) (April 1, 2025 – June 30, 2025)

Information on Net Sales and Profit or Loss Amounts by Reportable Segment

(Millions of yen)

	Reportable Segments			Others (Note 1)	Total	Adjustments (Note 2)	Quarterly Consolidated Income Statement Recorded amount (Note 3)
	Pharmaceutical Business	Animal Health Business	Overseas Business				
Net Sales							
Net Sales to External Customers	14,515	1,841	1,226	58	17,641	―	17,641
Inter-segment internal sales or transfers	―	―	―	17	17	(17)	―
Total	14,515	1,841	1,226	76	17,659	(17)	17,641
Segment Profit (Loss)	1,698	128	58	(2)	1,883	(418)	1,464

Note
1. "Others" comprises business segments not classified under the reportable segments, including clinical testing and medical devices.
2. The adjustment of (¥418) million to segment profit or loss (numbers in parentheses) consists of corporate expenses that have not been allocated to each business segment, and primarily comprises general and administrative expenses not attributable to any business segment.
3. Segment profit or loss (numbers in parentheses) has been adjusted against operating profit on the quarterly consolidated statement of income.
4. As described in "Notes on Business Combinations and Other Matters," the provisional accounting treatment for business combinations was finalized during the previous consolidated fiscal year. Accordingly, segment information for the first quarter of the previous consolidated fiscal year reflects the amounts after the significant revision of the initial allocation of acquisition costs resulting from the finalization of the provisional accounting treatment.

II. First Quarter of the Current Consolidated Fiscal Year (Cumulative) (April 1, 2026 – June 30, 2026)

Information on Net Sales and Profit or Loss Amounts by Reportable Segment

(Millions of yen)

	Reportable Segments			Others (Note 1)	Total	Adjustments (Note 2)	Quarterly Consolidated Income Statement Recorded amount (Note 3)
	Pharmaceutical Business	Animal Health Business	Overseas Business				
Net Sales							
Net Sales to External Customers	14,484	1,952	908	38	17,384	―	17,384
Inter-segment internal sales or transfers	―	―	―	16	16	(16)	―
Total	14,484	1,952	908	54	17,400	(16)	17,384
Segment Profit (Loss)	1,132	44	(35)	(8)	1,132	(420)	711

Note
1. "Others" comprises business segments not classified under the reportable segments, including clinical testing and medical devices.
2. The adjustment of (¥420) million to segment profit or loss (numbers in parentheses) consists of corporate expenses that have not been allocated to each business segment, and primarily comprises general and administrative expenses not attributable to any business segment.
3. Segment profit or loss (numbers in parentheses) has been adjusted against operating profit on the quarterly consolidated statement of income.

(Notes on Business Combinations, etc.)

Finalization of Provisional Accounting Treatment for Business Combinations

Provisional accounting treatment for the business combination with Ha Tay Pharmaceutical Joint Stock Company completed on December 31, 2024, was applied in the consolidated fiscal year before last, but was finalized in the third quarter of the previous consolidated fiscal year.

With the finalization of this provisional accounting treatment, the comparative information included in the quarterly consolidated financial statements for the first quarter of the previous consolidated fiscal year reflects a significant revision to the initial allocation of acquisition costs.

As a result, in the quarterly consolidated statement of income and statement of quarterly consolidated comprehensive income for the first quarter of the previous consolidated fiscal year, operating profit decreased by ¥14 million due to an increase of ¥14 million in selling, general and administrative expenses; ordinary profit and quarterly net income before income taxes each decreased by ¥25 million due to a decrease of ¥7 million in other non-operating income and an increase of ¥4 million in other non-operating expenses; quarterly profit attributable to owners of parent decreased by ¥15 million due to a decrease of ¥10 million in deferred income taxes; and quarterly profit attributable to owners of parent increased by ¥10 million due to a decrease of ¥25 million in quarterly profit attributable to non-controlling interests.

3. Supplementary Information

(1) Sales of Major Products of Operating Companies

Sales of Major Products
(Results for the First Quarter of the Fiscal Year Ending March 2027)

ASKA Pharmaceutical Co., Ltd. (Millions of yen)

Product		Previous Period Fiscal Year Ended March 31, 2026		Current Period Fiscal Year Ending March 31, 2027		YoY Change (%)
		First Quarter Results	Full Year Results	First Quarter Results	Full Year Forecast	
Uterine fibroids and endometriosis agent	RELUMINA	2,768	11,173	2,776	11,340	0.3
Thyroid hormone formulation	THYRADIN	2,125	8,775	2,257	9,082	6.2
Poorly absorbable rifamycin antimicrobial agent	RIFXIMA	1,902	7,883	1,982	8,023	4.2
Dysmenorrhea agent	DroEthi	2,022	8,312	1,946	7,678	(3.8)
Antihypertensive agent	CANDESARTAN*	2,074	7,884	1,814	7,213	(12.5)
LH-RH derivative microcapsule sustained-release agent	LEUPRORELIN	962	3,880	1,064	5,596	10.5
Dysmenorrhea agent	FREWELL	747	2,973	636	2,586	(14.8)
Progesterone agent	LUTEUM	538	2,270	553	2,197	2.9
Antithyroid agent	MERCAZOLE	406	1,654	434	1,745	6.7
Oral contraceptive	Slinda	74	392	241	1,019	224.9

*Including fixed-dose combination

ASKA Animal Health Co., Ltd. (Millions of yen)

Business field	Previous Period Fiscal Year Ended March 31, 2026		Current Period Fiscal Year Ending March 31, 2027		YoY Change (%)
	First Quarter Results	Full Year Results	First Quarter Results	Full Year Forecast	
Feed additives, mixed feed, feed ingredients	1,143	4,513	1,307	4,469	14.4
Veterinary pharmaceuticals	674	2,640	636	2,827	(5.7)